To assess the effects of circulating FGF21 on breast cancer, osmotic pumps containing FGF21 were used to mimic the levels of circulating FGF21 detected in NAFLD models (Fig. 5E and F). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.